Phuturdex › Diseases › Hypersensitivity
Drugs in development · updated 30 October 2026
Hypersensitivity: drugs in development
As of 30 October 2026 there are 10 active clinical trials (recruiting or ongoing, phases I–III) on 22 drugs for hypersensitivity. 2 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Bezuclastinib TabletsCGT9486 | II | 2 | NCT05186753 |
| ITI-9001 | I | 1 | NCT07726147 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| OmalizumabOmlyclo®, Xolair® | II | 2 | NCT07059091 |
| AmpicillinPolycillin-N®, Penbritin-S® | II | 1 | NCT06406114 |
| CefaclorCeclor Cd®, Ceclor® | II | 1 | NCT06406114 |
| Cefadroxil | II | 1 | NCT06406114 |
| CefdinirOmnicef® | II | 1 | NCT06406114 |
| CefepimeCefepime And Dextrose In Duplex Container®, Cefepime In Plastic Container® | II | 1 | NCT06406114 |
| CefiximeSuprax® | II | 1 | NCT06406114 |
| CefotaximeCefotaxime And Dextrose 2.4% In Plastic Container®, Cefotaxime And Dextrose 3.9% In Plastic Container® | II | 1 | NCT06406114 |
| Cefpodoxime | II | 1 | NCT06406114 |
| CeftazidimeCeftazidime In Dextrose Container®, Ceptaz® | II | 1 | NCT06406114 |
| CeftriaxoneROCEPHIN, Ceftriaxone And Dextrose In Duplex Container® | II | 1 | NCT06406114 |
| CefuroximeCefuroxime And Dextrose In Duplex Container®, Zinacef In Plastic Container® | II | 1 | NCT06406114 |
| CephalexinKeftab®, Keflet® | II | 1 | NCT06406114 |
| Histamine DihydrochlorideCeplene® | II | 1 | NCT06406114 |
| InulinInulin And Sodium Chloride® | II | 1 | NCT06372249 |
Sorted by most advanced phase and number of active trials. Showing 15 of 20 drugs.
All 22 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Atopic dermatitis 91 drugs
- Asthma 84 drugs
- Chronic urticaria 24 drugs
- Eczema 27 drugs
- Hereditary angioedema 8 drugs
- Dermatitis 29 drugs
- Peanut Hypersensitivity 11 drugs
- Eosinophilic esophagitis 8 drugs
- Seasonal allergic rhinitis 9 drugs
- Sarcoidosis 10 drugs
- Skin disease 34 drugs
- Chronic inducible urticaria 6 drugs
Broader categories
- Immune System Diseases 54 drugs
- Respiratory disease 57 drugs
- Otorhinolaryngologic disease 4 drugs
- Obstructive lung disease 4 drugs
- Lung disease 104 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006967 “Hypersensitivity”.